Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2013 June;54(3) > The Journal of Cardiovascular Surgery 2013 June;54(3):333-6

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

  INNOVATIONS IN DRUG-ELUTING TECHNOLOGY


The Journal of Cardiovascular Surgery 2013 June;54(3):333-6

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Femoropopliteal in-stent restenosis: review and potential for drug based therapy

Phillips J. 1, Ansel G. 2

1 Cardiology, Internal Medicine Ohio Health Riverside Methodist Hospital Columbus, OH, USA;
2 Cardiology, Internal Medicine Ohio Health Riverside Methodist Hospital Columbus, OH, USA


PDF  


Endovascular treatment of symptomatic peripheral arterial disease in the femoropopliteal (FP) artery is fraught with high rates of restenosis. Success of the antiproliferative drug, paclitaxel, in the coronary arteries, has lead to the investigation of paclitaxel in the peripheral arteries to treat restenosis. This article reviews restenosis rates for the major treatment modalities used in the FP segment. Use of drug-elution for restenosis is also reviewed, including the use of drug-eluting balloons and drug-eluting stents.

top of page

Publication History

Cite this article as

Corresponding author e-mail

gansel2@ohiohealth.com